MEDIMMUNE RECEIVES COMPLETE RESPONSE LETTER FROM FDA FOR NEW FLUMIST FORMULATION

MedImmune Inc. announced that it received complete response letter from the U.S. Food and Drug Administration for a supplemental biologics license application related to the new formulation of FluMist, the intranasal flu vaccine. MedImmune is seeking approval to use refrigerator-stable CAIV-T - cold adapted influenza vaccine trivalent, in preventing influenza in healthy individuals aged 5 to 49 years. Trading Markets (http://www.tradingmarkets.com/tm.site/news/BREAKING%20NEWS/308986/)